EGFR and cancer: SBS5 mainly caused mutations in the ERBB2 (such as “Signaling by ERBB2 in Cancer”, P = 1.6×10−4), EGFR (such as “Signaling by EGFR in Cancer”, P = 7.5×10−3), FGFR (such as “Signaling by FGFR in disease”, P = 9.1×10−3) and Non-RTK (such as “Signaling by PTK6”, P =1.5×10−3) signal pathways in various cancer types (Figure 4B; Supplementary Figure S11B).